Background: Although inactivation of the von Hippel-Lindau gene (VHL), located on chromosome 3p25, is considered to be a major cause of hemangioblastomas (HBs), the incidence of biallelic inactivation of VHL is reportedly low. The aim of this study was to determine the prevalence of VHL alterations in HBs, as well as to identify additional molecular aberrations. Methods: Genetic and epigenetic alterations were comprehensively and comparatively analyzed in 11 VHL-related and 21 sporadic HBs. Results: VHL alterations detected by sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis were more frequent in VHL-related HBs than in sporadic HBs (100% vs 62%; P = 0.029). VHL alterations were found only in 4 sporadic HBs by direct sequencing; however, targeted deep sequencing detected 9 additional alterations. Loss of heterozygosity (LOH) on chromosome 3 was found in 64% and 57% of VHL-related and sporadic HBs, respectively, by single nucleotide polymorphism (SNP) array analysis. Among 19 tumors with chromosome 3 LOH, 5 were classified as copy-neutral LOH. VHL promoter hypermethylation was detected only in sporadic HBs (33%), indicating that epigenetic suppression of VHL is a common mechanism in sporadic HBs. The rate of biallelic VHL inactivation among VHL-related and sporadic HBs was 64% and 52%, respectively. LOH on either chromosome 6 or 10 was detected only in sporadic HBs (43%). Conclusion: Although biallelic inactivation of VHL is a dominant mechanistic cause of the pathogenesis of HB, other unknown mechanisms may also be involved, and such mechanisms may be different between VHL-related and sporadic HB.
Background: Although inactivation of the von Hippel-Lindau gene (VHL), located on chromosome 3p25, is considered to be a major cause of hemangioblastomas (HBs), the incidence of biallelic inactivation of VHL is reportedly low. The aim of this study was to determine the prevalence of VHL alterations in HBs, as well as to identify additional molecular aberrations. Methods: Genetic and epigenetic alterations were comprehensively and comparatively analyzed in 11 VHL-related and 21 sporadic HBs. Results:VHL alterations detected by sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis were more frequent in VHL-related HBs than in sporadic HBs (100% vs 62%; P = 0.029). VHL alterations were found only in 4 sporadic HBs by direct sequencing; however, targeted deep sequencing detected 9 additional alterations. Loss of heterozygosity (LOH) on chromosome 3 was found in 64% and 57% of VHL-related and sporadic HBs, respectively, by single nucleotide polymorphism (SNP) array analysis. Among 19 tumors with chromosome 3 LOH, 5 were classified as copy-neutral LOH. VHL promoter hypermethylation was detected only in sporadic HBs (33%), indicating that epigenetic suppression of VHL is a common mechanism in sporadic HBs. The rate of biallelic VHL inactivation among VHL-related and sporadic HBs was 64% and 52%, respectively. LOH on either chromosome 6 or 10 was detected only in sporadic HBs (43%). Conclusion: Although biallelic inactivation of VHL is a dominant mechanistic cause of the pathogenesis of HB, other unknown mechanisms may also be involved, and such mechanisms may be different between VHL-related and sporadic HB.
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: S H Sprenger; J M Gijtenbeek; P Wesseling; R Sciot; F van Calenbergh; M Lammens; J W Jeuken Journal: J Neurooncol Date: 2001-05 Impact factor: 4.130
Authors: Sebsebe Lemeta; Yan Aalto; Mika Niemelä; Juha Jääskeläinen; Markku Sainio; Juha Kere; Sakari Knuutila; Tom Böhling Journal: Cancer Genet Cytogenet Date: 2002-03
Authors: Jude Fitzgibbon; Lan-Lan Smith; Manoj Raghavan; Matthew L Smith; Silvana Debernardi; Spyros Skoulakis; Debra Lillington; T Andrew Lister; Bryan D Young Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas Journal: Nat Genet Date: 2012-06-10 Impact factor: 38.330
Authors: Ganesh M Shankar; Amaro Taylor-Weiner; Nina Lelic; Robert T Jones; James C Kim; Joshua M Francis; Malak Abedalthagafi; Lawrence F Borges; Jean-Valery Coumans; William T Curry; Brian V Nahed; John H Shin; Sun Ha Paek; Sung-Hye Park; Chip Stewart; Michael S Lawrence; Kristian Cibulskis; Aaron R Thorner; Paul Van Hummelen; Anat O Stemmer-Rachamimov; Tracy T Batchelor; Scott L Carter; Mai P Hoang; Sandro Santagata; David N Louis; Fred G Barker; Matthew Meyerson; Gad Getz; Priscilla K Brastianos; Daniel P Cahill Journal: Acta Neuropathol Commun Date: 2014-12-24 Impact factor: 7.801
Authors: Hugh Furness; Louay Salfity; Johanna Devereux; Dorothy Halliday; Helen Hanson; Deborah M Ruddy; Neha Shah; George Sultana; Emma R Woodward; Richard N Sandford; Katie M Snape; Eamonn R Maher Journal: Genes (Basel) Date: 2021-09-15 Impact factor: 4.096